Could Johnson & Johnson’s talcum powder litigation, now in its second decade, come to an end in 2025? Or are more legal and legislative battles on the horizon?

Johnson & Johnson enters the New Year with a pending third talc bankruptcy, this time filed by subsidiary Red River Talc in the Southern District of Texas, and a proposed $10 billion plan to compensate victims of ovarian and other gynecological cancers. But many fights remain, most notably a Feb. 18 trial over key issues like the plan’s confirmation and possible dismissal of the Chapter 11 case.